A ( VEGF-A ). Its indications encompass the treatment of patients with Neovascular ( Wet ) Age-Related Macular Degeneration ( AMD ), Macular Edema Following Retinal Vein Occlusion ( RVO ), Diabetic Macular Edema ( DME ), Diabetic Retinopathy ( DR ) and Myopic Choroidal Neovascularization ( mCNV ).
Biocon Biologics receives MHRA , UK approval for YESAFILI , a biosimilar of Aflibercept
Biocon Biologics Limited ( BBL ), a subsidiary of Biocon , has announced that MHRA , Medicines and Healthcare products Regulatory Agency in the UK , has granted marketing authorization for YESAFILI ®, a biosimilar of Aflibercept . In September , YESAFILI ®, received marketing authorization approval from the European Commission ( EC ) for the European Union ( EU ). YESAFILI ®, an ophthalmology product , is intended for the treatment of neovascular ( wet AMD ) age-related macular degeneration , visual impairment due to macular oedema secondary to retinal vein occlusion ( branch RVO or central RVO ), visual impairment due to diabetic macular oedema ( DME ) and visual impairment due to myopic choroidal neovascularisation ( myopic CNV ). It is highly similar to the reference product Eylea ® ( aflibercept ). Data shows that YESAFILI ® has comparable quality , safety , and efficacy to Eylea ®.
BioTech
BioAsia 2024 to put spotlight on role of data & AI in reshaping future of lifesciencess
BioAsia , the pioneering annual event dedicated to the lifesciences sector , is all set to host its 21st edition , BioAsia 2024 from February 26 to 28 , 2024 in Hyderabad . The event themed “ Data and AI : Redefining Possibilities ,” is aimed at transforming the future of lifesciences . The keynote speakers include Dave Ricks , CEO of Eli Lilly , Dr . Chris Boerner , Incoming CEO of BMS ,
BIOVOICENEWS . COM 49